for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

58.15USD

Change

-0.38(-0.65%)

Volume

11,871,686

Today's Range

57.18

 - 

58.58

52 Week Range

57.04

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
58.53
Open
57.79
Volume
11,871,686
3M AVG Volume
206.90
Today's High
58.58
Today's Low
57.18
52 Week High
85.97
52 Week Low
57.04
Shares Out (MIL)
1,253.00
Market Cap (MIL)
72,904.07
Forward P/E
--
Dividend (Yield %)
4.68

Next Event

Dividend For GILD.OQ - 0.6800 USD

Latest Developments

More

Gilead Sciences Reports Q3 Non-GAAP Earnings Per Share Of $2.11

Gilead Sciences Says FDA Approved Antiviral Veklury (Remdesivir) For COVID-19

FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct 16

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Jyoti Mehra

Executive Vice President of Human Resources

Linda Higgins

Senior Vice President - Head of External Innovation

Key Stats

2.48 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

26.1K

2018

22.1K

2019

22.4K

2020(E)

24.2K
EPS (USD)

2017

8.840

2018

6.670

2019

6.630

2020(E)

6.988
Price To Earnings (TTM)
60.42
Price To Sales (TTM)
3.15
Price To Book (MRQ)
4.17
Price To Cash Flow (TTM)
37.77
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
2.45
Return on Equity (TTM)
2.06

Latest News

Latest News

Gilead cuts 2020 sales outlook as COVID-19 drug remdesivir falls short

Gilead Sciences Inc on Wednesday cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID-19.

Gilead quarterly revenue rises 17% on remdesivir sales

Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.

Gilead shares rise after United States approves remdesivir as COVID-19 drug

Shares of Gilead Sciences Inc rose 6% on Friday after its antiviral drug, remdesivir, became the first and only approved treatment for COVID-19 in the United States.

Gilead's remdesivir gets U.S. FDA approval for hospitalized COVID-19 patients

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

FACTBOX-Countries where remdesivir is approved or supported for treating COVID-19

Gilead Sciences Inc's remdesivir is at the forefront in the fight against the novel coronavirus as one of the first drugs to have shown to be effective in countering COVID-19 in human trials. On Thursday, the U.S. Food and Drug Administration approved remdesivir for treating...

Gilead's remdesivir gets U.S. FDA approval

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's remdesivir (Veklury). (Reporting by Vishwadha Chander in Bengaluru; Editing by Maju Samuel)

Remdesivir questioned by WHO trial; women take virus more seriously than men

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

EU urged to review remdesivir supply deal after COVID-19 trial results

The European Union should renegotiate a 1 billion euro ($1.2 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.

Row breaks out over WHO trial casting doubt on remdesivir as COVID-19 drug

A row broke out on Friday over a World Health Organization (WHO) clinical trial which concluded that the anti-viral drug remdesivir has little or no impact on a patient's chances of surviving COVID-19.

WHO trial to assess other antibody, antiviral drugs after remdesivir doubt

The World Health Organization said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID-19 treatments, after the trial found Gilead Science's remdesivir had no impact on survival rates.

CORRECTED-EU urged to review remdesivir supply deal after COVID trial results

The European Union should renegotiate a 1 billion euro ($1.17 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.

Gilead questions WHO study that cast doubts on drug's COVID-19 benefits

Gilead Sciences Inc <GILD.O> has questioned the findings of a World Health Organization (WHO) study that concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital.

Row breaks out over WHO trial casting doubt on remdesivir as COVID-19 drug

A row broke out on Friday over a World Health Organization (WHO) clinical trial which concluded that the anti-viral drug remdesivir has little or no impact on a patient's chances of surviving COVID-19.

WHO defends data after concluding Gilead's remdesivir flopped COVID trial

A World Health Organization (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated it said on Friday, as the U.S. company criticized its methodology.

BRIEF-Gilead Sciences Issues Statement On Solidarity Trial

* GILEAD SAYS ARE CONCERNED THAT THE DATA FROM THE OPENLABEL GLOBAL TRIAL HAVE NOT UNDERGONE RIGOROUS REVIEW

WHO study says remdesivir did not reduce mortality in COVID-19 patients - FT

Gilead Sciences Inc's remdesivir had no substantial effect on COVID-19 patients' chances of survival, a clinical trial by the World Health Organization (WHO) has found, the Financial Times reported on Thursday.

NIH starts clinical trial testing antibody treatments in COVID-19 patients

The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.

EU makes 1 billion-euro bet on Gilead's COVID drug before trial results

The European Union has agreed to pay more than 1 billion euros ($1.2 billion) to Gilead <GILD.O> for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication.

Late-stage study of COVID-19 convalescent-plasma treatment with remdesivir starts

A late-stage trial testing the combination of Gilead Sciences' remdesivir and a highly concentrated solution of antibodies that neutralize the COVID-19 virus has begun, the National Institutes of Health (NIH) said on Thursday.

Gilead's remdesivir shaved five days off COVID-19 recovery time, reduced risk of death in some

Final data from Gilead Sciences Inc's <GILD.O> antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up